Drug Profile
Nitric oxide mimetics - Cellegy
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Cellegy Pharmaceuticals
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 31 Dec 2006 Discontinued - Phase-I for Prostate cancer in USA (unspecified route)
- 28 Nov 2005 Cellegy and New Harbour Corporation have entered into a licensig agreement for nitric oxide donor therapy in China for the treatment of anal disorders
- 02 May 2003 Phase-I clinical trials in Prostate cancer in USA